Press Releases

HOUSTON, Aug. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its proof of concept clinical trial to evaluate its p-STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cel

BETHESDA, Md., Aug. 13, 2019 /PRNewswire/ -- Healthy Directions LLC, a subsidiary of Adaptive Health, LLC, is proud to announce its corporate sponsorship of Vitamin Angels, a global public health nonprofit that distributes lifesaving vitamins and minerals to women and children in need around the world.

MONMOUTH JUNCTION, N.J., Aug. 13, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its

VANCOUVER, Aug. 13, 2019 /PRNewswire/ - Choom™ (CSE: CHOO; OTCQB: CHOOF), an emerging adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that it has signed a purchase agreement (the "Agreement") to acquire Ninetails Cannabis Inc. ("Ninetails"), a licensed c

CUPERTINO, Calif., Aug. 13, 2019 /PRNewswire/ -- Corinth MedTech, a medical device company and the developer of the Veloxion™ System for relieving th

PRINCETON, N.J., Aug. 13, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended

TARRYTOWN, N.Y., Aug. 13, 2019 /PRNewswire/ -- EYLEA is the only anti-VEGF approved to treat four retinal conditions with a single dose strength prefilled syringeEYLEA is available in multiple dosing intervals, offering doctors flexibility to address patients' individual needs

HOLLISTON, Mass., Aug. 13, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-thr

ST. LOUIS, Aug. 13, 2019 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced that it is expanding its offerings in the 2020 Health Insurance Marketplace, or exchange. The company is expanding its footprint in ten markets: Arizona, Florida, Georgia

- FDA agrees to allow initiation of NODE-303 open-label safety study without test dose and in population consistent with ongoing studies -- NODE-301 trial upsized from 100 to 150 adjudicated PSVT events to satisfy EMA requirements; Company remains on track for topline readout in 1H20 -- Company to host mid-year business update conference call today at 8:00 a.m. ET